Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (9): 877-881.DOI: 10.3969/j.issn.1673-8640.2022.09.017
Previous Articles Next Articles
WANG Rui, LI Zhaoyan, ZHAO Aiguang()
Received:
2021-03-15
Revised:
2021-11-22
Online:
2022-09-30
Published:
2022-10-25
Contact:
ZHAO Aiguang
CLC Number:
WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer[J]. Laboratory Medicine, 2022, 37(9): 877-881.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.09.017
年份 | 文献 | 胃癌组/例 | 对照组/例 | 样本来源 | 变异方式 | 检测技术 | 突变基因 | 临床用途 |
---|---|---|---|---|---|---|---|---|
2015年 | MARTIGNANO等[ | 60 | 30 | 血浆 | 突变 | Droplet digital PCR | HER-2 | 治疗标志物 |
2015年 | KWAK等[ | 1 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | MET | 治疗标志物 |
2019年 | MATHAI等[ | 70 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | HER-2 | 治疗标志物 |
2019年 | MARTIGNANO等[ | 277 | 0 | 血浆、肿瘤组织 | 突变 | Mass ARRAY | TP53、PIK3CA、ERBB2、KRAS | 诊断/预后的生物标志物 |
年份 | 文献 | 胃癌组/例 | 对照组/例 | 样本来源 | 变异方式 | 检测技术 | 突变基因 | 临床用途 |
---|---|---|---|---|---|---|---|---|
2015年 | MARTIGNANO等[ | 60 | 30 | 血浆 | 突变 | Droplet digital PCR | HER-2 | 治疗标志物 |
2015年 | KWAK等[ | 1 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | MET | 治疗标志物 |
2019年 | MATHAI等[ | 70 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | HER-2 | 治疗标志物 |
2019年 | MARTIGNANO等[ | 277 | 0 | 血浆、肿瘤组织 | 突变 | Mass ARRAY | TP53、PIK3CA、ERBB2、KRAS | 诊断/预后的生物标志物 |
[1] |
CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
DOI URL |
[2] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
DOI URL |
[3] |
ZHENG R, ZENG H, ZHANG S, et al. Estimates of cancer incidence and mortality in China,2013[J]. Chin J Cancer, 2017, 36(1):66.
DOI URL |
[4] | 常敏, 张久聪, 周琴, 等. 胃癌流行病学研究进展[J]. 胃肠病学和肝病学杂志, 2017, 26(9):966-969. |
[5] |
WARTON K, SAMIMI G. Methylation of cell-free circulating DNA in the diagnosis of cancer[J]. Front Mol Biosci, 2015, 2:13.
DOI PMID |
[6] |
YANG S, TALBI A, WANG X, et al. Pharmacokinetics study of calf thymus DNA in rats and beagle dogs with(3)H-labeling and tracing method[J]. J Pharm Biomed Anal, 2014, 88:60-65.
DOI URL |
[7] | BRONKHORST A J, UNGERER V, HOLDENRIEDER S. The emerging role of cell-free DNA as a molecular marker for cancer management[J]. Biomol Detect Quantif, 2019, 17:100087. |
[8] |
KUSTANOVICH A, SCHWARTZ R, PERETZ T, et al. Life and death of circulating cell-free DNA[J]. Cancer Biol Ther, 2019, 20(8):1057-1067.
DOI PMID |
[9] |
ZHOU J, CHANG L, GUAN Y, et al. Application of circulating tumor DNA as a non-invasive tool for monitoring the progression of colorectal cancer[J]. PLoS One, 2016, 11(7):e0159708.
DOI URL |
[10] | 高明正, 张瑾, 潘云, 等. 循环肿瘤DNA研究进展及其临床应用现状[J]. 实用医药杂志, 2019, 36(7):664-668. |
[11] | PERKINS G, LU H, GARLAN F, et al. Droplet-based digital PCR:application in cancer research[J]. Adv Clin Chem, 2017, 79:43-91. |
[12] | MERKER J D, OXNARD G R, COMPTON C, et al. Circulating tumor DNA analysis in patients with cancer:American Society of Clinical Oncology and College of American Pathologists joint review[J]. J Clin Oncol, 2018, 36(16):1631-1641. |
[13] |
DEANS Z C, BUTLER R, CHEETHAM M, et al. IQN path ASBL report from the first European cfDNA consensus meeting:expert opinion on the minimal requirements for clinical ctDNA testing[J]. Virchows Arch, 2019, 474(6):681-689.
DOI URL |
[14] |
COHEN J D, LI L, WANG Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378):926-930.
DOI PMID |
[15] | LI Q, WU R, WU F, et al. KMT2D promotes proliferation of gastric cancer cells:evidence from ctDNA sequencing[J]. J Clin Lab Anal, 2021, 35(4):e23721. |
[16] |
GAO Y, ZHANG K, XI H, et al. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer:a meta-analysis[J]. Oncotarget, 2017, 8(4):6330-6340.
DOI URL |
[17] |
LING Z Q, LV P, LU X X, et al. Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer[J]. PLoS One, 2013, 8(6):e67195.
DOI URL |
[18] |
UCHÔA GUIMARÃES C T, FERREIRA MARTINS N N, CRISTINA DA SILVA OLIVEIRA K, et al. Liquid biopsy provides new insights into gastric cancer[J]. Oncotarget, 2018, 9(19):15144-15156.
DOI PMID |
[19] |
CHEN M, ZHAO H. Next-generation sequencing in liquid biopsy:cancer screening and early detection[J]. Hum Genomics, 2019, 13(1):34.
DOI URL |
[20] |
QIU M Z, LI Q, WANG Z Q, et al. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients:a prospective cohort observation[J]. Int J Cancer, 2014, 134(10):2468-2477.
DOI URL |
[21] |
SHODA K, ICHIKAWA D, FUJITA Y, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer[J]. Gastric Cancer, 2017, 20(1):126-135.
DOI PMID |
[22] |
WANG D S, LIU Z X, LU Y X, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer[J]. Gut, 2019, 68(7):1152-1161.
DOI URL |
[23] |
PECTASIDES E, STACHLER M D, DERKS S, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma[J]. Cancer Discov, 2018, 8(1):37-48.
DOI PMID |
[24] | LIU Y, YANG M, JIANG T, et al. Quantitative analysis of HER2 amplification by droplet digital PCR in the follow-up of gastric cancer patients being treated with trastuzumab after surgery[J]. Gastroenterol Res Pract, 2019, 2019:1750329. |
[25] |
AGUILAR-MAHECHA A, JOSEPH S, CAVALLONE L, et al. Precision medicine tools to guide therapy and monitor response to treatment in a HER-2+ gastric cancer patient:case report[J]. Front Oncol, 2019, 9:698.
DOI URL |
[26] |
JIN Y, CHEN D L, WANG F, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors[J]. Mol Cancer, 2020, 19(1):154.
DOI PMID |
[27] |
WANG Y, ZHAO C, CHANG L, et al. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer[J]. EBioMedicine, 2019, 43:261-269.
DOI PMID |
[28] |
SHAHJEHAN F, KAMATHAM S, KASI P M. Role of circulating tumor DNA in gastrointestinal cancers:update from abstracts and sessions at ASCO 2018[J]. Front Oncol, 2019, 9:358.
DOI URL |
[29] |
DU J, WU X, TONG X, et al. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification[J]. Oncotarget, 2017, 8(16):26281-26287.
DOI PMID |
[30] |
ZHANG C, CHEN Z, CHONG X, et al. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies[J]. Clin Transl Med, 2020, 10(8):e254.
DOI PMID |
[31] | KIM Y W, KIM Y H, SONG Y, et al. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer[J]. Exp Mol Med, 2019, 51(8):1-10. |
[32] |
LI J, LI Z, DING Y, et al. TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer[J]. PeerJ, 2021, 9:e11146.
DOI URL |
[33] |
MATHAI R A, VIDYA R V S, REDDY B S, et al. Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors:implications in the precision oncology[J]. J Clin Med, 2019, 8(3):373.
DOI URL |
[34] |
KINUGASA H, NOUSO K, TANAKA T, et al. Droplet digital PCR measurement of HER2 in patients with gastric cancer[J]. Br J Cancer, 2015, 112(10):1652-1655.
DOI URL |
[35] |
KWAK E L, AHRONIAN L G, SIRAVEGNA G, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer[J]. Cancer Discov, 2015, 5(12):1271-1281.
DOI PMID |
[36] |
ROLFO C, CARDONA A F, CRISTOFANILLI M, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice:perspective of the International Society of Liquid Biopsy(ISLB)[J]. Crit Rev Oncol Hematol, 2020, 151:102978.
DOI URL |
[37] |
MARTIGNANO F. Cell-free DNA: an overview of sample types and isolation procedures[J]. Methods Mol Biol, 2019, 1909:13-27.
DOI PMID |
[1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[2] | SUN Zepeng, WANG Hongbin, WANG Jiandong, SONG Dewei, XIAO Peng. Analysis and progress of peptide and protein biomarker methodology for myocardial injury [J]. Laboratory Medicine, 2023, 38(8): 784-789. |
[3] | ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598. |
[4] | GAO Feng. Clinical application of novel tumor biomarkers:prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306. |
[5] | LIU Ruili, LI Lanjun, JIA Minlei, WANG Yihui, HAO Weina. Correlation between tumor miR-7-5p and NOVA2 levels and clinical prognosis in cancer tissues of patients with gastric cancer [J]. Laboratory Medicine, 2023, 38(4): 325-329. |
[6] | WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195. |
[7] | ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210. |
[8] | GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996. |
[9] | LU Qiyuan, LU Jianhua. Biomarker research progress for the diagnosis of periprosthetic joint infection [J]. Laboratory Medicine, 2023, 38(10): 997-1002. |
[10] | CHEN Xuewei, LI Yirong. Candidate biomarkers in metabolic syndrome based on GEO database [J]. Laboratory Medicine, 2023, 38(1): 32-38. |
[11] | WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99. |
[12] | NIE Tian, RAN Zihan, JIN Lei. Research progress on the relationship between interleukin gene polymorphisms and gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 882-886. |
[13] | WU Yanqian, YU Chong, SHEN Lu, ZHENG Haoran, HONG Yeting. Research progress of body fluid piRNA as a potential biomarker of disease [J]. Laboratory Medicine, 2022, 37(8): 782-786. |
[14] | JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, DONG Wei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Yifei. Expression level of lncRNA SNHG15 in gastric cancer and clinical significance [J]. Laboratory Medicine, 2022, 37(5): 409-412. |
[15] | LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||